Capricor Therapeutics, Inc. · 1 month ago
Accounts Payable Specialist
San Diego, CA
Full-time
Onsite
Entry Level
$25/hr - $30/hr
2+ years expCapricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. They are seeking an Accounts Payable Specialist responsible for end-to-end accounts payable processing, ensuring accurate and timely payment of vendor invoices while maintaining strong internal controls.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Processing of high-volume vendor invoices with accuracy
Perform 2-way and 3-way matching
Reconcile vendor statements and resolve discrepancies, short payments, and billing issues
Maintain vendor data including onboarding, updates, and compliance documentation
Respond to internal and external inquiries regarding invoice and payment status
Support month-end close activities
Ensure adherence to company policies and SOX controls
Assist with audits by providing supporting documentation
Identify process improvement opportunities to enhance efficiency and accuracy
Qualification
Required
Bachelor's degree in finance or a related field
Minimum of 2 years of Accounts Payable experience
Experience performing 2-way and 3-way invoice matching
Strong vendor reconciliation experience
NetSuite experience (required)
Strong Excel Skills (VLOOKUP/XLOOKUP, pivot tables)
Excellent attention to detail and organizational skills
Ability to manage priorities and meet deadlines
Strong written and verbal communication skills
Preferred
Experience in biotechnology preferred but not required
Company
Capricor Therapeutics, Inc.
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$329.5MKey Investors
Nippon ShinyakuNational Institutes of HealthCalifornia Institute for Regenerative Medicine
2025-12-05Post Ipo Equity· $150M
2024-10-17Post Ipo Equity· $75M
2024-09-17Post Ipo Equity· $15M
Leadership Team
AJ Bergmann
Chief Financial Officer
Recent News
2026-01-09
Company data provided by crunchbase